Intelligence Feed event · Equity · 2026-09-26

    C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS

    Question

    C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS

    Direct answer

    C4 Therapeutics reported new clinical biomarker data at the 23rd International Myeloma Society (IMS) Annual Meeting from its Phase 1 trial evaluating cemsidomide plus dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients. The presentation highlighted robust biomarker evidence of immune activation. In addition, C4 released initial data from its Phase 1b combination study pairing cemsidomide with Pfizer's bispecific antibody elranatamab (ELREXFIO).

    Original publisher
    Market Ontology
    Evidence through
    2026-09-26
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS”, revision 1, evidence through 2026-09-26. https://marketontology.com/market-events/2026-09-26/c4-therapeutics-presents-cemsidomide-phase-1-biomarker-data-at-ims-dd39e9

    EQUITY
    C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS
    C4 Therapeutics reported new clinical biomarker data at the 23rd International Myeloma Society (IMS) Annual Meeting from its Phase 1 trial evaluating cemsidomide plus dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients. The presentation highlighted robust biomarker evidence of immune activation. In addition, C4 released initial data from its Phase 1b combination study pairing cemsidomide with Pfizer's bispecific antibody elranatamab (ELREXFIO).
    CCCCPFE
    Impact
    61
    SEP 26
    SIG
    85%
    CCCCPFE
    C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS
    C4 Therapeutics reported new clinical biomarker data at the 23rd International Myeloma Society (IMS) Annual Meeting from its Phase 1 trial evaluating cemsidomide plus dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients. The presentation highlighted robust biomarker evidence of immune activation. In addition, C4 released initial data from its Phase 1b combination study pairing cemsidomide with Pfizer's bispecific antibody elranatamab (ELREXFIO).
    → Demonstrated proof-of-mechanism biomarker response in refractory multiple myeloma alters probability-of-success models for CCCC clinical pipeline assets.
    Impact
    C4 Therapeutics reported new clinical biomarker data at the 23rd International Myeloma Society (IMS) Annual Meeting from its Phase 1 trial evaluating cemsidomide plus dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients. The presentation highlighted robust biomarker evidence of immune activation. In addition, C4 released initial data from its Phase 1b combination study pairing cemsidomide with Pfizer's bispecific antibody elranatamab (ELREXFIO).
    Affected
    CCCCPFE
    Transmission
    Demonstrated proof-of-mechanism biomarker response in refractory multiple myeloma alters probability-of-success models for CCCC clinical pipeline assets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CCCCclinical biomarker validation driving targeted oncology pipeline valuationUp1-5dC4 Therapeutics presented Phase 1 biomarker data demonstrating robust T-cell activation at IMS.
    PFEcombination therapy utility for elranatamab oncology portfolioWatch1-4wCemsidomide evaluated in Phase 1b combination with Pfizer's elranatamab (ELREXFIO).

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    CCCCUpdisagreed2.98 2026-09-25+4.53%-1.01%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month